User:Mr. Ibrahem/Mavacamten
Clinical data | |
---|---|
Trade names | Camzyos |
Other names | MYK-461 |
AHFS/Drugs.com | Monograph |
License data |
|
Routes of administration | By mouth |
Drug class | Cardiac myosin inhibitor |
Legal status | |
Legal status | |
Identifiers | |
| |
Chemical and physical data | |
Formula | C15H19N3O2 |
Molar mass | 273.336 g·mol−1 |
3D model (JSmol) | |
| |
|
Mavacamten, sold under the brand name Camzyos, is a medication used to treat hypertrophic obstructive cardiomyopathy (HCOM).[2] It is taken by mouth.[2]
Common side effects include dizziness and syncope.[2] Other side effects may include heart failure.[2] Use in pregnancy may harm the baby.[2] It is a cardiac myosin inhibitor.[2]
Mavacamten was approved for medical use in the United States in 2022.[2] It is not available in Europe or the United Kingdom as of 2022.[3] In the United States a month of medication costs about 7,800 USD.[4]
References[edit]
- ^ "Archive copy". Archived from the original on 2022-11-13. Retrieved 2022-11-29.
{{cite web}}
: CS1 maint: archived copy as title (link) - ^ a b c d e f g h i j "Camzyos- mavacamten capsule, gelatin coated". DailyMed. 28 April 2022. Archived from the original on 3 July 2022. Retrieved 15 May 2022.
- ^ "Mavacamten". SPS - Specialist Pharmacy Service. 19 October 2018. Archived from the original on 24 June 2022. Retrieved 12 December 2022.
- ^ "Camzyos Prices, Coupons, Copay & Patient Assistance". Drugs.com. Archived from the original on 22 May 2023. Retrieved 12 December 2022.